Tsu F Yeh1,2, Chung M Chen1,3,4, Shou Y Wu5, Zahid Husan5, Tsai C Li6,7, Wu S Hsieh8, Chang H Tsai2,9, Hung C Lin2. 1. 1 Maternal Child Health Research Center, College of Medicine, and. 2. 2 Department of Pediatrics, Children's Hospital, and. 3. 4 Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 4. 3 Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan. 5. 5 Division of Neonatology, John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois. 6. 6 Graduate Institute of Biostatistics, College of Public Health, China Medical University, Taichung, Taiwan. 7. 7 Department of Healthcare Administration, College of Health Science, and. 8. 8 Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. 9. 9 Department of Biotechnology, Asian University, Taichung, Taiwan; and.
Abstract
RATIONALE: Bronchopulmonary dysplasia (BPD) is an important complication of mechanical ventilation in preterm infants, and no definite therapy can eliminate this complication. Pulmonary inflammation plays a crucial role in its pathogenesis, and glucocorticoid is one potential therapy to prevent BPD. OBJECTIVES: To compare the effect of intratracheal administration of surfactant/budesonide with that of surfactant alone on the incidence of death or BPD. METHODS: A clinical trial was conducted in three tertiary neonatal centers in the United States and Taiwan, in which 265 very-low-birth-weight infants with severe respiratory distress syndrome who required mechanical ventilation and inspired oxygen (fraction of inspired oxygen, ≥50%) within 4 hours of birth were randomly assigned to one of two groups (131 intervention and 134 control). The intervention infants received surfactant (100 mg/kg) and budesonide (0.25 mg/kg), and the control infants received surfactant only (100 mg/kg), until each infant required inspired O2 at less than 30% or was extubated. MEASUREMENTS AND MAIN RESULTS: The intervention group had a significantly lower incidence of BPD or death (55 of 131 [42.0%] vs. 89 of 134 [66%]; risk ratio, 0.58; 95% confidence interval, 0.44-0.77; P < 0.001; number needed to treat, 4.1; 95% confidence interval, 2.8-7.8). The intervention group required significantly fewer doses of surfactant than did the control group. The intervention group had significantly lower interleukin levels (IL-1, IL-6, IL-8) in tracheal aspirates at 12 hours and lower IL-8 at 3-5 and 7-8 days. CONCLUSIONS: In very-low-birth-weight infants with severe respiratory distress syndrome, intratracheal administration of surfactant/budesonide compared with surfactant alone significantly decreased the incidence of BPD or death without immediate adverse effect. Clinical trial registered with www.clinicaltrials.gov (NCT-00883532).
RCT Entities:
RATIONALE: Bronchopulmonary dysplasia (BPD) is an important complication of mechanical ventilation in preterm infants, and no definite therapy can eliminate this complication. Pulmonary inflammation plays a crucial role in its pathogenesis, and glucocorticoid is one potential therapy to prevent BPD. OBJECTIVES: To compare the effect of intratracheal administration of surfactant/budesonide with that of surfactant alone on the incidence of death or BPD. METHODS: A clinical trial was conducted in three tertiary neonatal centers in the United States and Taiwan, in which 265 very-low-birth-weight infants with severe respiratory distress syndrome who required mechanical ventilation and inspired oxygen (fraction of inspired oxygen, ≥50%) within 4 hours of birth were randomly assigned to one of two groups (131 intervention and 134 control). The intervention infants received surfactant (100 mg/kg) and budesonide (0.25 mg/kg), and the control infants received surfactant only (100 mg/kg), until each infant required inspired O2 at less than 30% or was extubated. MEASUREMENTS AND MAIN RESULTS: The intervention group had a significantly lower incidence of BPD or death (55 of 131 [42.0%] vs. 89 of 134 [66%]; risk ratio, 0.58; 95% confidence interval, 0.44-0.77; P < 0.001; number needed to treat, 4.1; 95% confidence interval, 2.8-7.8). The intervention group required significantly fewer doses of surfactant than did the control group. The intervention group had significantly lower interleukin levels (IL-1, IL-6, IL-8) in tracheal aspirates at 12 hours and lower IL-8 at 3-5 and 7-8 days. CONCLUSIONS: In very-low-birth-weight infants with severe respiratory distress syndrome, intratracheal administration of surfactant/budesonide compared with surfactant alone significantly decreased the incidence of BPD or death without immediate adverse effect. Clinical trial registered with www.clinicaltrials.gov (NCT-00883532).
Authors: Noah H Hillman; T Brett Kothe; Augusto F Schmidt; Matthew W Kemp; Emily Royse; Erin Fee; Fabrizio Salomone; Michael W Clarke; Gabrielle C Musk; Alan H Jobe Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-10-16 Impact factor: 5.464
Authors: Roberta L Keller; Eric C Eichenwald; Anna Maria Hibbs; Elizabeth E Rogers; Katherine C Wai; Dennis M Black; Philip L Ballard; Jeanette M Asselin; William E Truog; Jeffrey D Merrill; Mark C Mammel; Robin H Steinhorn; Rita M Ryan; David J Durand; Catherine M Bendel; Ellen M Bendel-Stenzel; Sherry E Courtney; Ramasubbareddy Dhanireddy; Mark L Hudak; Frances R Koch; Dennis E Mayock; Victor J McKay; Jennifer Helderman; Nicolas F Porta; Rajan Wadhawan; Lisa Palermo; Roberta A Ballard Journal: J Pediatr Date: 2017-01-16 Impact factor: 4.406
Authors: Joseph E Rower; David J Anderson; Catherine M Sherwin; Christopher A Reilly; Philip L Ballard; Cindy T McEvoy; Diana G Wilkins Journal: J Pharm Biomed Anal Date: 2019-01-29 Impact factor: 3.935
Authors: Rosemary D Higgins; Alan H Jobe; Marion Koso-Thomas; Eduardo Bancalari; Rose M Viscardi; Tina V Hartert; Rita M Ryan; Suhas G Kallapur; Robin H Steinhorn; Girija G Konduri; Stephanie D Davis; Bernard Thebaud; Ronald I Clyman; Joseph M Collaco; Camilia R Martin; Jason C Woods; Neil N Finer; Tonse N K Raju Journal: J Pediatr Date: 2018-03-16 Impact factor: 4.406